Pneumonia caused by crizotinib: case report and review of literature.

Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer.

Late-onset severe pneumonitis under osimertinib.

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Fatal interstitial lung disease associated with AZD9291.

Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer.

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

AZD9291-induced Acute Interstitial Lung Disease.

Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment.

Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision.